<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIVAGLOBIN- human immunoglobulin g solution </strong><br>CSL Behring LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Vivaglobin safely and effectively. See full prescribing information for Vivaglobin.<br> <br>Vivaglobin<br>Immune Globulin Subcutaneous (Human)<br>16% Liquid<br>Initial U.S. Approval: 2006</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="60%">
<col align="left" valign="middle" width="60%">
<col align="right" valign="middle" width="40%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Dosage and Administration (<a href="#S2.3">2.3</a>)</td>
<td align="right">04/2010</td>
</tr>
<tr class="Botrule Last">
<td align="left">Warnings and Precautions (<a href="#S5.1">5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>)</td>
<td align="right">04/2010</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Vivaglobin is an Immune Globulin Subcutaneous (Human) (IGSC), 16% Liquid indicated for the treatment of primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) (<a href="#S1">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For subcutaneous infusion <span class="Italics">only</span>. DO NOT INJECT INTO A BLOOD VESSEL.</span> </p>
<p class="Highlighta">Start patients on treatment with Vivaglobin 1 week after having received Immune Globulin Intravenous (Human) (IGIV) infusions at regular intervals for a period of at least 3 months. </p>
<p class="Highlighta"><span class="Bold">Initial Weekly Dose</span> (<a href="#S2.3">2.3</a>) </p>
<p class="Highlighta">The initial weekly dose of Vivaglobin is calculated to achieve a systemic serum IgG exposure (area under the concentration-time curve [AUC]) not inferior to the AUC of the previous IGIV treatment. </p>
<ul class="Disc">
<li>Vivaglobin weekly dose (in grams [g]) = <span class="Underline">1.37 x previous IGIV dose (g)</span><br>                                                                        No. of weeks between IGIV doses</li>
<li>Divide by 0.16 to convert the dose in g to milliliters (mL).</li>
</ul>
<p class="Highlighta"><span class="Bold">Dose Adjustment</span> (<a href="#S2.3">2.3</a>, <a href="#table1">Table 1</a>) </p>
<ul class="Disc">
<li>Doses may need to be adjusted over time based on the patient's clinical response and serum <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) trough levels.</li>
<li>To determine if a dose adjustment should be considered, measure the serum IgG trough level during IGIV therapy prior to switching to Vivaglobin and again after 2 to 3 months of treatment with Vivaglobin. Adjust the Vivaglobin dose to achieve a serum IgG trough level that is equal to the last trough level during prior IGIV therapy plus 180 mg/dL.</li>
</ul>
<p class="Highlighta"><span class="Bold">Administration</span> (<a href="#S2.4">2.4</a>) </p>
<ul class="Disc">
<li>Infuse subcutaneously, preferably in the abdomen, thigh, upper arm, and/or lateral hip.</li>
<li>Divide doses &gt;15 mL and infuse into multiple sites that are at least two inches apart. 							<ul class="Circle">
<li>Adults – Up to six simultaneous sites</li>
<li>Children &lt;45 kg (99 pounds) – Up to three simultaneous sites</li>
<li>Patients ≥65 years – Up to four simultaneous sites</li>
</ul>							If necessary, additional sites can be used consecutively during an infusion. 							</li>
<li>Administer at a rate of ≤20 mL/hour per site. The maximum infusion rate should not exceed a total of 3 mg/kg/minute (1.13 mL/kg/hour) for all simultaneous infusion sites combined.</li>
<li>Ensure that patients are not volume depleted.</li>
</ul>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">16% IgG (160 mg/mL) for subcutaneous infusion (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Anaphylactic or severe systemic reaction to Immune Globulin (Human) (<a href="#S4">4</a>)</li>
<li>IgA-deficient patients with antibodies against IgA or a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>IgA-deficient patients with antibodies against IgA are at greater risk of developing severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. Discontinue use if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs. Epinephrine should be immediately available to treat any acute severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<a href="#S5.1">5.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome has been reported to occur infrequently with IGIV treatment and with Vivaglobin treatment (<a href="#S5.2">5.2</a>).</li>
<li>Monitor patients for reactions reported to occur with IGIV treatment that may occur with Vivaglobin, including renal dysfunction/failure, thrombotic events, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, and transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) (<a href="#S5.3">5.3</a>).</li>
<li>Vivaglobin is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (<a href="#S5.4">5.4</a>).</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (observed in ≥5% of study subjects) were local injection-site reactions (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span> (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>The passive transfer of antibodies may interfere with the response to live virus vaccines (<a href="#S7.1">7.1</a>).</li>
<li>The passive transfer of antibodies may lead to misinterpretation of the results of serological testing (<a href="#S7.2">7.2</a>).</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pregnancy: No human or animal data. Use only if clearly needed (<a href="#S8.1">8.1</a>).</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Self-Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Preparation and Handling</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dosage</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome (AMS)</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Reactions Reported with IGIV Treatment</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Transmissible Infectious Agents</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Live Virus Vaccines</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Serological Testing</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1	US-Canada Study</a></h2>
<h2><a href="#section-11.2" class="toc">14.2	Europe-Brazil Study</a></h2>
<h1><a href="#section-12" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-13" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1	Self-Administration</a></h2>
<h2><a href="#section-14.2" class="toc">17.2	Additional Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">Vivaglobin is an Immune Globulin Subcutaneous (Human) (IGSC), 16% Liquid indicated as replacement therapy for primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI). This includes, but is not limited to, the primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> in common variable <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For subcutaneous infusion <span class="Italics">only</span>. DO NOT INJECT INTO A BLOOD VESSEL.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Self-Administration</h2>
<p class="First">Self-administration is appropriate for some patients. If self-administration is planned, the healthcare professional should provide the patient with instructions and training for subcutaneous infusion in the home or other appropriate setting (<span class="Italics">see <a href="#S17.1">Patient Counseling Information [17.1]</a> and the <a href="#FDA">FDA-Approved Patient Labeling</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Preparation and Handling</h2>
<p class="First">Vivaglobin is a colorless to light brown solution. Do not use if the solution is cloudy (turbid) or contains particulates.</p>
<ul class="Disc">
<li>Prior to administration, bring the Vivaglobin vial(s) to room temperature. Then, visually inspect each vial for particulate matter by gently swirling the vial, and check for discoloration by holding it up to the light.</li>
<li>Check the product expiration date on the vial label. Do not use beyond the expiration date.</li>
<li>Do not mix Vivaglobin with other products.</li>
<li>Do not shake the Vivaglobin vial.</li>
<li>Use aseptic technique when preparing and administering Vivaglobin.</li>
<li>The Vivaglobin vial is for single-use only. Discard all administration equipment and any unused product immediately after each infusion in accordance with local requirements.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dosage</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The dose should be individualized based on the patient's clinical response to Vivaglobin therapy and serum immunoglobulin (IgG) trough levels.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Begin treatment with Vivaglobin one week after the patient has received a regularly scheduled Immune Globulin Intravenous (Human) (IGIV) infusion. Prior to receiving treatment with Vivaglobin, patients need to have been receiving IGIV treatment for at least 3 months at dosing intervals of either every 3 weeks or every 4 weeks.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The initial weekly dose of Vivaglobin is established by converting the monthly IGIV dose into a weekly equivalent and increasing it using a dose adjustment factor (<span class="Italics">see <a href="#IWD">Initial Weekly Dose</a></span>). The goal is to achieve a systemic serum IgG exposure (area under the concentration-time curve [AUC]) not inferior to the AUC of the previous IGIV treatment (<span class="Italics">see <a href="#S12.3">Pharmacokinetics [12.3]</a></span>).</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Prior to switching treatment from IGIV to Vivaglobin, obtain the patient's serum IgG trough level to guide subsequent dose adjustment (<span class="Italics">see <a href="#DA">Dose Adjustment</a></span>). After 2 to 3 months, weekly administration of Vivaglobin will lead to stable steady-state serum IgG levels with lower IgG peak levels and higher IgG trough levels compared with monthly IGIV treatment.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="IWD"></a><a name="section-2.3.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Initial Weekly Dose</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">To calculate the initial weekly dose of Vivaglobin, multiply the previous IGIV dose in grams (g) by the dose adjustment factor of 1.37, then divide this dose by the number of weeks between doses during the patient's previous IGIV treatment (i.e., 3 or 4).</span></p>
<table width="50%">
<col align="left" valign="top" width="45%">
<col align="center" valign="top" width="55%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">IGSC weekly dose (g) = </td>
<td align="center"><span class="XmChange"><span class="Underline">1.37 × previous IGIV dose (g)</span></span></td>
</tr>
<tr class="Botrule Last">
<td align="left"></td>
<td align="center">Number of weeks between IGIV doses</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">To convert the Vivaglobin dose (g) to milliliters (mL), divide the dose in grams (g) by 0.16.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DA"></a><a name="section-2.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Dose Adjustment</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Over time, the dose may need to be adjusted to achieve the desired clinical response and serum IgG trough level. To determine if a dose adjustment should be considered, measure the patient's serum IgG trough level on IGIV prior to switching to Vivaglobin and every 2 to 3 months after switching from IGIV to Vivaglobin.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">To achieve the same AUC with Vivaglobin as with the previous IGIV treatment, follow these steps:</span></p>
<ol>
<li style="border-left:1px solid;">
<span class="XmChange">Estimate the target serum IgG trough level on weekly Vivaglobin treatment, which is derived as follows:</span><br> <br><span class="XmChange">Target concentration (mg/dL) during Vivaglobin treatment = the last trough level during prior IGIV treatment + 180 mg/dL</span>
</li>
<li style="border-left:1px solid;">
<span class="XmChange">In Table 1, find the additional Vivaglobin dose to be administered, based on the patient's body weight, and the difference between the target IgG concentration (mg/dL) and the observed trough level during Vivaglobin treatment.</span><br> <br><span class="XmChange"><span class="Bold">Additional dosage increments may be indicated based on the patient's clinical response (<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> frequency and severity).</span></span>
</li>
</ol>
<a name="table1"></a><table width="100%">
<caption><span>Table 1:  Adjustment (±mL) of the Weekly Vivaglobin Dose Based on the Difference (±mg/dL) From the Target Serum IgG Trough Level<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="7%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="3"><span class="XmChange">Difference From Target IgG Trough Level<a href="#footnote-1" class="Sup">*</a> (mg/dL)</span></th>
<th class="Rrule" align="center" colspan="13">Body Weight (kg)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center">10</th>
<th class="Rrule" align="center">15</th>
<th class="Rrule" align="center">20</th>
<th class="Rrule" align="center">30</th>
<th class="Rrule" align="center">40</th>
<th class="Rrule" align="center">50</th>
<th class="Rrule" align="center">60</th>
<th class="Rrule" align="center">70</th>
<th class="Rrule" align="center">80</th>
<th class="Rrule" align="center">90</th>
<th class="Rrule" align="center">100</th>
<th class="Rrule" align="center">110</th>
<th class="Rrule" align="center">120</th>
</tr>
<tr class="Last"><th class="Rrule" align="center" colspan="13">Dose Adjustment (mL per Week)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th></tr>
</thead>
<tfoot><tr><td colspan="14" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Target IgG concentration (mg/dL) during Vivaglobin treatment equals the last observed trough level during prior IGIV treatment plus 180 mg/dL.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Dose adjustment in mL is based on the slope of the serum IgG trough level response to Vivaglobin dose increments (6.1 mg/dL per increment of 1 mg/kg per week).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">100</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">150</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">200</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">250</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">31</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">300</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">37</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">350</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">43</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">400</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">49</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">450</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">55</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">500</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">61</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">For example, if a patient with a body weight of 70 kg has an actual IgG trough level of 900 mg/dL and the target trough level is 1000 mg/dL, this results in a difference of 100 mg/dL. Therefore, increase the weekly dose of Vivaglobin by 7 mL.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor the patient's clinical response, and repeat the dose adjustment process as needed.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Administration</h2>
<p class="First"><span class="Bold">Vivaglobin is for subcutaneous infusion <span class="Italics">only</span>. DO NOT INJECT INTO A BLOOD VESSEL.</span></p>
<p>Vivaglobin is for subcutaneous infusion, preferably in the abdomen, thigh, upper arm, and/or lateral hip. Multiple injection sites should be at least two inches apart, and the actual point of injection should be changed with each weekly administration.</p>
<ul class="Disc">
<li>Infusion volume – Do not exceed 15 mL per site. Divide doses greater than 15 mL and infuse into a maximum of three simultaneous sites for children weighing less than 45 kg (99 pounds), a maximum of six simultaneous sites for adults up to age 65, and a maximum of four simultaneous sites for patients 65 years of age and older. If necessary, additional sites can be used consecutively during an infusion.</li>
<li>Infusion rate – The maximum recommended infusion rate is 20 mL per hour per site and should not exceed a total of 3.0 mg/kg/minute (1.13 mL/kg/hour) for all simultaneous injection sites combined.</li>
</ul>
<p>Ensure that patients are not volume depleted.</p>
<p>Follow the steps below and use aseptic technique to administer Vivaglobin. For information about subcutaneous infusion in the home or other appropriate setting, <span class="Italics">see <a href="#S17.1">Patient Counseling Information (17.1)</a></span>.</p>
<table width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Assemble supplies –</span> Place the Vivaglobin vial(s) and all supplies needed for the infusion on a clean, flat surface.</dd>
</dl></td></tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Thoroughly wash and dry hands –</span> The use of gloves when preparing and administering Vivaglobin is optional.</dd>
</dl></td></tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">Clean the vial stopper –</span> Remove the protective cap from the vial to expose the central portion of the rubber stopper. Clean the stopper with alcohol and allow it to dry.</dd>
</dl></td></tr>
<tr>
<td align="left"><dl class="Disc">
<dt class="Bold">4.</dt>
<dd>
<span class="Bold">Prepare and fill the syringe(s) –</span> Using a sterile syringe and needle, pull back on the plunger to draw air into the syringe that is equal to the amount of Vivaglobin to be withdrawn. Then, insert the needle into the vial stopper and inject the air into the vial.  Finally, withdraw the desired volume of Vivaglobin. If multiple vials are required to achieve the desired dose, repeat this step with another syringe.</dd>
</dl></td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-01.jpg"></td>
</tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">5.</dt>
<dd>
<span class="Bold">Fill and prime the infusion pump –</span> Follow the manufacturer's instructions for filling the pump reservoir and for preparing the pump, administration tubing, and Y-site connection tubing, if needed. Be sure to prime the administration tubing to ensure that no air is left in the tubing or needle by filling the tubing/needle with Vivaglobin.</dd>
</dl></td></tr>
<tr>
<td align="left"><dl class="Disc">
<dt class="Bold">6.</dt>
<dd>
<span class="Bold">Select the injection site(s) –</span> The number and location of injection sites depends on the volume of the total dose. Doses greater than 15 mL should be divided and infused into multiple sites that are at least two inches apart. The recommended number of simultaneous injection sites is up to six for adults, up to three for children who weigh less than 45 kg (99 pounds) and up to four for patients ages 65 and over. If necessary, additional injection sites can be used consecutively.</dd>
</dl></td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-02.jpg"></td>
</tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">7.</dt>
<dd>
<span class="Bold">Clean the injection site(s) –</span> Using an antiseptic solution, clean each site beginning at the center and working outward in a circular motion. Allow each site to dry before proceeding.</dd>
</dl></td></tr>
<tr>
<td align="left"><dl class="Disc">
<dt class="Bold">8.</dt>
<dd>
<span class="Bold">Insert the needle –</span> Based on the patient's body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, grasp or spread the skin; then insert the needle into the subcutaneous tissue.</dd>
</dl></td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-03.jpg"></td>
</tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">9.</dt>
<dd>
<span class="Bold">Check for proper placement of the needle. Vivaglobin must not be injected into a blood vessel –</span> After inserting each needle into the subcutaneous tissue and before starting the infusion, test to make sure that a blood vessel has not been accessed accidentally. To do this, attach a sterile syringe to the end of the primed administration tubing, gently pull back on the plunger, and see if any blood is flowing back into the tubing. If blood is present, remove and discard the needle and administration tubing. Repeat steps 5 and 8 (priming and needle insertion) using a new needle, new administration tubing, and a different injection site.</dd>
</dl></td></tr>
<tr>
<td align="left"><dl class="Disc">
<dt class="Bold">10.</dt>
<dd>
<span class="Bold"> Secure the needle to the skin –</span> Apply sterile gauze or transparent dressing over each site to hold the needle in place. If using multiple, simultaneous injection sites, secure the Y-site connection tubing to the administration tubing.</dd>
</dl></td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-04.jpg"></td>
</tr>
<tr><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">11.</dt>
<dd>
<span class="Bold">Infuse Vivaglobin –</span> Follow the manufacturer's instructions to turn on the pump.</dd>
</dl></td></tr>
<tr class="Botrule Last"><td align="left" colspan="2"><dl class="Disc">
<dt class="Bold">12.</dt>
<dd>
<span class="Bold">Record the infusion –</span> Remove the peel-off portion of the label from each vial used, and affix it to the patient record.</dd>
</dl></td></tr>
</tbody>
</table>
<p>After administration, immediately discard any unused product and administration equipment in accordance with local procedures.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Vivaglobin is a solution containing 16% IgG (160 mg/mL) for subcutaneous infusion.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">Vivaglobin is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of Immune Globulin (Human).</p>
<p>Vivaglobin is contraindicated in IgA-deficient patients with antibodies against IgA or a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<span class="Italics">see <a href="#S11">Description [11]</a></span>).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may occur (<span class="Italics">see <a href="#S17.2">Patient Counseling Information [17.2]</a></span>). In case of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, discontinue the Vivaglobin infusion immediately and institute appropriate treatment. Epinephrine should be immediately available to treat any acute severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Individuals with <span class="product-label-link" type="condition" conceptid="433171" conceptname="Selective immunoglobulin A deficiency">IgA deficiency</span> can develop anti-IgA antibodies and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) after administration of blood components containing IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. Vivaglobin contains ≤1.7 mg/mL IgA (<span class="Italics">see <a href="#S11">Description [11]</a></span>). The minimum concentration of IgA that will provoke a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is not known; therefore all IgG preparations carry the risk of inducing an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to IgA.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome (AMS)</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">AMS has been reported to occur infrequently with IGIV treatment<span class="Sup">5</span> and with Vivaglobin treatment. The syndrome usually begins within several hours to 2 days following IGIV treatment. AMS is characterized by signs and symptoms including severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Cerebrospinal fluid (CSF) studies frequently show <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and with elevated protein levels up to several hundred mg/dL. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients exhibiting such signs and symptoms should receive a thorough neurological examination, including CSF studies, to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Reactions Reported with IGIV Treatment</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The following reactions have been reported to occur with IGIV treatment and may occur with IGSC treatment.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Renal Dysfunction/Failure</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Renal dysfunction/failure, osmotic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur with use of human immune globulin products. Ensure that patients are not volume depleted and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of Vivaglobin and at appropriate intervals thereafter.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.<span class="Sup">1</span> If renal function deteriorates, consider discontinuing Vivaglobin. For patients judged to be at risk of developing renal dysfunction because of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or predisposition to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (such as those with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, those who are overweight or use concomitant nephrotoxic medicinal products, or those who are over 65 years of age), administer Vivaglobin at the minimum rate practicable.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="Bold" style="border-left:1px solid;"><span class="XmChange">Thrombotic Events</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Thrombotic events may occur with use of human immune globulin products.<span class="Sup">2-4</span> Patients at risk may include those with a history of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, multiple cardiovascular risk factors, advanced age, impaired <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, hypercoagulable disorders, <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of immobilization, and/or known or suspected hyperviscosity. Because of the potentially increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients judged to be at risk of developing thrombotic events, administer Vivaglobin at the minimum rate practicable.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Vivaglobin may contain blood group antibodies that may act as hemolysins and induce <span class="Italics">in vivo</span> coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin (Coombs') test result and <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.<span class="Sup">6-8</span>  Delayed <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> can develop subsequent to immune globulin therapy due to enhanced RBC sequestration, and acute <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, consistent with <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span>, has been reported.<span class="Sup">9</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor recipients of Vivaglobin for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. If these are present after Vivaglobin infusion, perform appropriate confirmatory laboratory testing. If transfusion is indicated for patients who develop <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> with clinically compromising <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> after receiving Vivaglobin, perform adequate cross-matching to avoid exacerbating on-going <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.4"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> may occur in patients administered human immune globulin products.<span class="Sup">10</span>  <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Typically, it occurs within 1 to 6 hours following transfusion. Patients with <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed using oxygen therapy with adequate ventilatory support.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor recipients of Vivaglobin for pulmonary adverse reactions. If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Transmissible Infectious Agents</h2>
<p class="First">Because Vivaglobin is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of Vivaglobin. Report all <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought possibly to have been transmitted by Vivaglobin to the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>. The physician should discuss the risks and benefits of this product with the patient before prescribing or administering it to the patient (<span class="Italics">see <a href="#S17.2">Patient Counseling Information [17.2]</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Laboratory Tests</h2>
<p class="First">After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs') test.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions (those AEs considered by the investigator to be at least possibly related to Vivaglobin administration) observed in ≥5% of study subjects receiving Vivaglobin were local injection-site reactions (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First"><span class="Italics">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">US-Canada Study</span></p>
<p>The safety of Vivaglobin was evaluated in a clinical study in the US and Canada for 12 months in 65 subjects with PI who had been previously treated with IGIV every 3 or 4 weeks (<span class="Italics">see <a href="#S14.1">Clinical Studies [14.1]</a></span>). After 3 months, subjects were switched from IGIV to weekly subcutaneous administration of Vivaglobin for 12 months. Subjects were treated weekly with Vivaglobin at a mean dose of 158 mg/kg body weight (range: 34 to 352 mg/kg). The 65 subjects received a total of 3,656 infusions of Vivaglobin. </p>
<p>Table 2 shows the number of subjects who withdrew from the US-Canada study due to adverse events (AEs) and the AEs leading to discontinuation.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2: Subjects with Adverse Events (AEs) Leading to Discontinuation, US-Canada Study</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">AEs</th>
<th class="Rrule" align="center">Subjects with AEs<span class="Italics"> At Least Possibly Related</span>
</th>
<th class="Rrule" align="center">Subjects with AEs <span class="Italics">Irrespective of Causality</span>
</th>
<th class="Rrule" align="center">Total Number (%) of Subjects</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>One subject experienced <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Subjects with at least 1 AE leading to discontinuation</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5 (8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injection-site reaction</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">3 (5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal obstruction</span></td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span></td>
<td class="Rrule" align="center">1<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">1<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
</tbody>
</table>
<p>Table 3 summarizes the most frequent AEs (experienced by more than 5% of subjects), <span class="Italics">irrespective of causality</span>. It includes all AEs and those considered temporally associated with the Vivaglobin infusion, i.e., occurring during the infusion or within 72 hours after the end of the infusion.</p>
<a name="table3"></a><table width="100%">
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First Toprule"><th class="Botrule" align="center" colspan="5">Table 3:  Incidence of Subjects With Adverse Events (AEs)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> (Experienced by &gt;5% of Subjects) and Rate<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a> per Infusion<span class="Italics">, Irrespective of Causality</span>, in the US-Canada Study</th></tr>
<tr>
<th class="Lrule Rrule" align="center"></th>
<th class="Botrule Rrule" align="center" colspan="2">All AEs</th>
<th class="Botrule Rrule" align="center" colspan="2">AEs Occurring During or Within 72 Hours of Infusion</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center">AEs<a href="#footnote-4" class="Sup">*</a><br> (&gt;5% of Subjects)</th>
<th class="Rrule" align="center">Number (%) of Subjects<br>(n=65)</th>
<th class="Rrule" align="center">Number (Rate<a href="#footnote-5" class="Sup">†</a>) of AEs per Infusion<br>(n=3656)</th>
<th class="Rrule" align="center">Number (%) of Subjects<br>(n=65)</th>
<th class="Rrule" align="center">Number (Rate<a href="#footnote-5" class="Sup">†</a>) of AEs per Infusion<br>(n=3656)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Excluding <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Rate, number of AEs per infusion.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Includes injection-site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">AEs at the injection site<span class="Bold"><a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a></span>
</td>
<td class="Botrule Rrule" align="center">60 (92%)</td>
<td class="Botrule Rrule" align="center">1789 (0.49)</td>
<td class="Botrule Rrule" align="center">60 (92%)</td>
<td class="Botrule Rrule" align="center">1767 (0.4848)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Other AEs</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">31 (48%)</td>
<td class="Rrule" align="center">159 (0.04)</td>
<td class="Rrule" align="center">30 (46%)</td>
<td class="Rrule" align="center">104 (0.033)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorder</span></td>
<td class="Rrule" align="center">24 (37%)</td>
<td class="Rrule" align="center">35 (0.01)</td>
<td class="Rrule" align="center">18 (28%)</td>
<td class="Rrule" align="center">24 (0.007)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">16 (25%)</td>
<td class="Rrule" align="center">28 (0.008)</td>
<td class="Rrule" align="center">12 (8%)</td>
<td class="Rrule" align="center">20 (0.005)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">12 (18%)</td>
<td class="Rrule" align="center">18 (0.005)</td>
<td class="Rrule" align="center">11 (17%)</td>
<td class="Rrule" align="center">15 (0.004)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">11 (17%)</td>
<td class="Rrule" align="center">22 (0.006)</td>
<td class="Rrule" align="center">10 (15%)</td>
<td class="Rrule" align="center">16 (0.004)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span></td>
<td class="Rrule" align="center">10 (15%)</td>
<td class="Rrule" align="center">17 (0.005)</td>
<td class="Rrule" align="center">8 (12%)</td>
<td class="Rrule" align="center">11 (0.003)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span></td>
<td class="Rrule" align="center">7 (11%)</td>
<td class="Rrule" align="center">8 (0.002)</td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">6 (9%)</td>
<td class="Rrule" align="center">8 (0.002)</td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">4 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">6 (9%)</td>
<td class="Rrule" align="center">6 (0.002)</td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></td>
<td class="Rrule" align="center">6 (9%)</td>
<td class="Rrule" align="center">6 (0.002)</td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">6 (0.002)</td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">2 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorder</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">7 (0.002)</td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">8 (0.002)</td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">4 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">4 (0.001)</td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">3 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">4 (0.001)</td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">2 (0.001)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">5 (0.001)</td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">2 (0.001)</td>
</tr>
</tbody>
</table>
<p>The total number of AEs, <span class="Italics">irrespective of causality,</span> including injection-site reactions, that began during or within 72 hours after the end of an infusion was 2262 (a rate of 0.62 AEs per infusion); excluding injection-site reactions, the rate of AEs per infusion was 0.14.</p>
<p>Table 4 summarizes the severity of local AEs by infusion, <span class="Italics">irrespective of causality</span>.</p>
<a name="table4"></a><table width="80%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First Toprule"><th class="Botrule" align="center" colspan="3">Table 4:  Severity of Local Adverse Events (AEs) by Infusion, <span class="Italics">Irrespective of Causality,</span> in the US-Canada Study</th></tr>
<tr>
<th class="Lrule Rrule" align="center">AEs<br>
</th>
<th class="Rrule" align="center" rowspan="2">Number (Rate<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>) of AEs</th>
<th class="Rrule" align="center" rowspan="2">Number (Rate<a href="#footnote-7" class="Sup">*</a>) of AEs Occurring During or Within 72 Hours of Infusion</th>
</tr>
<tr class="Last"><th class="Lrule Rrule" align="left">(Number of infusions: 3656)<br><br>
</th></tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Rate, number of AEs per infusion.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Defined as those reactions that did not interfere with routine activities.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Defined as those reactions that interfered with routine activities.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>Defined as those reactions that made it impossible to perform routine activities.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">AEs at the injection site</td>
<td class="Rrule" align="center">1789 (0.49)</td>
<td class="Rrule" align="center">1767 (0.48)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mild<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">1112 (0.30)</td>
<td class="Rrule" align="center">1100 (0.30)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Moderate<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">601 (0.16)</td>
<td class="Rrule" align="center">593 (0.16)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Severe<a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>
</td>
<td class="Rrule" align="center">65 (0.02)</td>
<td class="Rrule" align="center">64 (0.02)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Unknown severity </td>
<td class="Rrule" align="center">11 (&lt;0.01)</td>
<td class="Rrule" align="center">10 (&lt;0.01)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinuations due to AEs at the injection site</td>
<td class="Rrule" align="center" colspan="2" valign="middle">3 subjects</td>
</tr>
</tbody>
</table>
<p>Of the three subjects who discontinued the study due to injection-site reactions, one withdrew on Day 1 (Infusion 1) of the wash-in/wash-out period after a moderate injection-site reaction and a mild <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; one withdrew on Day 22 (Infusion 4) of the wash-in/wash-out period following severe injection-site reactions for two weeks; and one withdrew on Day 78 following a mild injection-site reaction.</p>
<p>Local reactions decreased substantially after repeated use.</p>
<p>Table 5 summarizes the most frequent adverse reactions (experienced by at least 3% of subjects) and considered by the investigator to be <span class="Italics">at least possibly related</span> to Vivaglobin administration.</p>
<a name="table5"></a><table width="80%">
<caption><span>Table 5:  Incidence of Subjects With Adverse Reactions (Experienced in ≥3% of Subjects) and Rate<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> per Infusion in the US-Canada Study</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Related Adverse Reactions<br>(≥3% Subjects)</th>
<th class="Rrule" align="center">Number (%) of Subjects<br>(n=65)</th>
<th class="Rrule" align="center">Number (Rate<a href="#footnote-11" class="Sup">*</a>) of Adverse Reactions per Infusion<br>(n=3656)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Rate, number of adverse reactions per infusion.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Includes injection-site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Adverse reactions at the injection site<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>
</td>
<td class="Rrule" align="center">60 (92%)</td>
<td class="Rrule" align="center">1787 (0.49)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Other Adverse reactions</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">21 (32%)</td>
<td class="Rrule" align="center">59 (0.016)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">7 (11%)</td>
<td class="Rrule" align="center">9 (0.002)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">4 (6%)</td>
<td class="Rrule" align="center">9 (0.002)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">3 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorder</span></td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">3 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">2 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorder</span></td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">3 (0.001)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">2 (0.001)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">Urine abnormality</span></td>
<td class="Rrule" align="center">2 (3%)</td>
<td class="Rrule" align="center">3 (0.001)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Europe-Brazil Study</span></p>
<p>In a clinical study conducted in Europe and Brazil, the efficacy and safety of Vivaglobin were evaluated for 10 months in 60 subjects with PI. Subjects were treated weekly with Vivaglobin at a mean dose of 89 mg/kg body weight (range: 51 to 147 mg/kg), which was 101% of their previous weekly IGIV or IGSC dose (<span class="Italics">see <a href="#S14.2">Clinical Studies [14.2]</a></span>). Study subjects received a total of 2,297 infusions of Vivaglobin.</p>
<p>The AEs and their rates reported in this study were similar to those reported in the US-Canada study, with two exceptions: no episodes of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> were reported; and 18 (a rate of 0.008 per infusion) episodes of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> were judged to be related to the administration of Vivaglobin. One subject discontinued due to repeated local reactions of moderate severity.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First"><span class="Italics">Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Vivaglobin</span></p>
<p>Adverse reactions identified during worldwide postmarketing use of Vivaglobin for treatment of PI are allergic-<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and other cutaneous reactions, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">throat swelling</span>), generalized reactions (including flu-like symptoms, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gastrointestinal cramping, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> possibly caused by <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, and injection-site reactions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold">General</span></p>
<p>The following adverse reactions have been identified and reported during the postmarketing use of IGIV products<span class="Sup">11</span>:</p>
<ul class="Disc">
<li>
<span class="Italics">Renal: </span>Acute renal dysfunction/failure, osmotic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span></li>
<li>
<span class="Italics">Respiratory:  </span><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></li>
<li>
<span class="Italics">Cardiovascular:  </span><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></li>
<li>
<span class="Italics">Neurological:  </span><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome</li>
<li>
<span class="Italics">Integumentary:  </span><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span></li>
<li>
<span class="Italics">Hematologic:  </span><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, positive direct antiglobulin (Coombs') test</li>
<li>
<span class="Italics">General/Body as a Whole:</span>  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></li>
<li>
<span class="Italics">Musculoskeletal:  </span><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></li>
<li>
<span class="Italics">Gastrointestinal:  </span>Hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
</ul>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Live Virus Vaccines</h2>
<p class="First">The passive transfer of antibodies with immunoglobulin administration may interfere with the response to live virus vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>/<span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>/<span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> (<span class="Italics">see <a href="#S17.2">Patient Counseling Information [17.2]</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Serological Testing</h2>
<p class="First">Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with Vivaglobin. It is also not known whether Vivaglobin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Vivaglobin should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Vivaglobin has not been evaluated in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<ul class="Disc">
<li>In the US-Canada study, Vivaglobin was evaluated in 6 children (ages 5 through 11) and 4 adolescents (ages 13 through 16). In the Europe-Brazil study, Vivaglobin was evaluated in 16 children (ages 3 through 11) and 6 adolescents (ages 13 through 16).</li>
<li>The safety and efficacy of Vivaglobin were not studied in pediatric subjects under 2 years of age.</li>
<li>There were no differences in the safety and efficacy profiles as compared with adult subjects.</li>
<li>No pediatric-specific dosing requirements were necessary to achieve the desired serum IgG levels.</li>
<li>For recommendations on the number of simultaneous injection sites for pediatric patients who weigh less than 45 kg (99 pounds), <span class="Italics">see <a href="#S2.4">Administration (2.4)</a></span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">The clinical studies of Vivaglobin did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. For recommendations on the number of simultaneous injection sites for geriatric patients, see <span class="Italics"><a href="#S2.4">Administration (2.4)</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Vivaglobin is a sterile solution consisting of pasteurized, polyvalent immune globulin for subcutaneous administration. Vivaglobin is manufactured from large pools of human plasma by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> alcohol fractionation and is not chemically altered or enzymatically degraded. Vivaglobin is a 16% (160 mg/mL) protein solution, with a content of at least 96% IgG. Vivaglobin contains ≤1.7 mg/mL IgA and ≤1.8 mg/mL IgM. The distribution of IgG subclasses is similar to that present in normal human plasma. Vivaglobin also contains 2.25% glycine, 0.3% sodium chloride, and water for injection, USP. The pH of Vivaglobin is 6.4 to 7.2. Vivaglobin contains no preservative.</p>
<p>All plasma units used in the manufacture of Vivaglobin have been tested using serological assays for <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">hepatitis B surface antigen</span> and antibodies to HIV-1/2 and HCV as well as Nucleic Acid Testing (NAT) for HIV-1 and HCV and found to be nonreactive (negative). For HBV, an investigational NAT procedure is used and the plasma found to be negative; however, the significance of a negative result has not been established. In addition, the plasma has been tested by NAT for HAV and B19V. Only plasma that passed virus screening is used for production, and the limit for B19V in the fractionation pool is set not to exceed 10<span class="Sup">4</span> IU of B19V DNA per mL.</p>
<p>The capacity of the manufacturing process to remove and/or inactivate enveloped and non-enveloped viruses has been validated by laboratory spiking studies on a scaled-down process model, using enveloped and non-enveloped viruses. The virus reduction capacity of two steps (ethanol – fatty alcohol / pH precipitation and pasteurization in aqueous solution at 60°C for 10 hours) was evaluated. Total mean cumulative virus reductions ranged from 9.0 to ≥14.1 log<span class="Sub">10</span> as shown in Table 6.</p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6:	Mean Virus Reduction Factors</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Virus Studied</th>
<th class="Rrule" align="center">Ethanol – Fatty Alcohol / pH Precipitation<br>[log<span class="Sub">10</span>]</th>
<th class="Rrule" align="center">Pasteurization<br>[log<span class="Sub">10</span>]</th>
<th class="Rrule" align="center">Total Cumulative<br>[log<span class="Sub">10</span>]</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">HIV-1, human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1, model for HIV-1/2; BVDV, bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus, model for HCV and WNV (West Nile virus); PRV, pseudorabies virus, model for large enveloped DNA viruses (e.g., herpes virus); PEV, porcine enterovirus, model for HAV (in an immune globulin product); CPV, canine parvovirus, model for B19V.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Reduction of B19V (evaluated using porcine IgG) by pasteurization was ≥5.0 log<span class="Sub">10</span>.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4">Enveloped Viruses</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HIV-1</td>
<td class="Rrule" align="center">≥6.2</td>
<td class="Rrule" align="center">≥6.5</td>
<td class="Rrule" align="center">≥12.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">BVDV</td>
<td class="Rrule" align="center">≥5.3</td>
<td class="Rrule" align="center">≥8.7</td>
<td class="Rrule" align="center">≥14.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">WNV</td>
<td class="Rrule" align="center">≥4.4</td>
<td class="Rrule" align="center">≥9.3</td>
<td class="Rrule" align="center">≥13.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PRV</td>
<td class="Rrule" align="center">≥6.2</td>
<td class="Rrule" align="center">≥7.9</td>
<td class="Rrule" align="center">≥14.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">Non-enveloped Viruses</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PEV</td>
<td class="Rrule" align="center">≥6.7</td>
<td class="Rrule" align="center">3.7</td>
<td class="Rrule" align="center">≥10.4</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CPV</td>
<td class="Rrule" align="center">6.7</td>
<td class="Rrule" align="center">2.3<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</td>
<td class="Rrule" align="center">9.0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Vivaglobin supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The mechanism of action in PI has not been fully elucidated.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">The bioavailability of Vivaglobin is approximately 73% compared with IGIV, but can vary significantly among patients (<span class="Italics">see <a href="#S14.1">Clinical Studies [14.1]</a></span>). With Vivaglobin, peak serum IgG levels are lower than those achieved with IGIV. Subcutaneous administration results in relatively stable steady-state serum IgG levels when the product is dosed on a weekly basis.<span class="Sup">12-13</span></p>
<p>The pharmacokinetics (PK) of Vivaglobin were evaluated in the clinical study conducted in the US and Canada (<span class="Italics">see <a href="#S14">Clinical Studies [14.1]</a></span>). Subjects previously treated with IGIV were switched to weekly subcutaneous treatment with Vivaglobin. After a 3-month wash-in/wash-out period, doses were adjusted individually aiming to provide an IgG systemic exposure (AUC) that was not inferior to the AUC of the previous weekly-equivalent IGIV dose.</p>
<p>For the 19 per-protocol subjects completing the wash-in/wash-out period, the average dose adjustment for Vivaglobin was 137% ± 21% SD (range: 103% to 192%) of the previous weekly-equivalent IGIV dose. Following 10 to 12 weeks of treatment with Vivaglobin at this individually adjusted dose, the final steady-state AUC determinations were made in 17 of the 19 per-protocol subjects. The geometric mean ratio of the steady-state AUCs, standardized to a weekly treatment period, for Vivaglobin versus IGIV treatment, was 94.5% (range: 71.4% to 110.1%) with a lower 95% confidence limit of 89.8% for the 17 subjects. </p>
<p>Table 7 summarizes additional pharmacokinetic parameters for this study including dosing and serum IgG peak and trough levels following treatment with IGIV and Vivaglobin.</p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7:	Additional Pharmacokinetic Parameters, US-Canada Study</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">IGIV</th>
<th class="Rrule" align="center">Vivaglobin</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>For IGIV, weekly-equivalent dose.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">Number of Subjects</td>
<td class="Botrule Rrule" align="center">17</td>
<td class="Botrule Rrule" align="center">17</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Dose<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Mean</td>
<td class="Rrule" align="center">120 mg/kg</td>
<td class="Rrule" align="center">165 mg/kg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Range</td>
<td class="Rrule" align="center">55-243 mg/kg</td>
<td class="Rrule" align="center">63<span class="Bold">-</span>319 mg/kg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">IgG peak levels</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Mean</td>
<td class="Rrule" align="center">1735 mg/dL</td>
<td class="Rrule" align="center">1163 mg/dL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Range</td>
<td class="Rrule" align="center">1110-3230 mg/dL</td>
<td class="Rrule" align="center">743-2240 mg/dL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">IgG trough levels</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Mean</td>
<td class="Rrule" align="center">883 mg/dL</td>
<td class="Rrule" align="center">1064 mg/dL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">    Range</td>
<td class="Rrule" align="center">430-1600 mg/dL</td>
<td class="Rrule" align="center">547-2140 mg/dL</td>
</tr>
</tbody>
</table>
<p>The 6-month clinical study conducted in Europe and Brazil in 60 subjects with PI also included a PK evaluation. Subjects were treated weekly with Vivaglobin at a mean dose of 89 mg/kg body weight (range: 51 to 147 mg/kg), which was 101% of their previous weekly IGIV or IGSC dose (<span class="Italics">see <a href="#S14.2">Clinical Studies [14.2]</a></span>). After the subjects had reached steady state with weekly administration of Vivaglobin, peak serum IgG levels were observed after a mean of 2.5 days (range: 0 to 7 days) in 41 subjects.</p>
<p>In both studies, the serum IgG levels in subjects receiving weekly subcutaneous therapy with Vivaglobin were relatively stable in contrast to serum IgG levels observed with monthly IGIV treatment (rapid peaks followed by a slow decline).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-11.1"></a><p></p>
<h2>14.1	US-Canada Study</h2>
<p class="First">The open-label, prospective, multicenter clinical study conducted in the US and Canada evaluated the pharmacokinetics, efficacy, safety, and tolerability of Vivaglobin in 65 (51 per-protocol) adult and pediatric subjects with PI. Subjects previously receiving monthly treatment with IGIV were switched to weekly subcutaneous administration of Vivaglobin for 12 months, after a 3-month wash-in/wash-out period.</p>
<p>The study evaluated the annual rate of serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (defined as bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>, and visceral <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>). The annual rate of any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was also evaluated.</p>
<p>In this study, the volume of Vivaglobin infused (using administration tubing and an infusion pump) did not exceed 15 mL per injection site at a rate of 20 mL per hour per site. Doses greater than 15 mL were divided and infused into multiple sites using Y-site connection tubing. For recommendations on the number of simultaneous injection sites for pediatric patients weighing less than 45 kg (99 pounds), see <span class="Italics"><a href="#S2.4">Administration (2.4)</a></span>.</p>
<p>Table 8 summarizes the dosing and annual rate of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> for the 51 per-protocol subjects in efficacy phase of the US-Canada study.</p>
<a name="table8"></a><table width="70%">
<caption><span>Table 8:  Dose and Annual Rate of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> with Vivaglobin – Per-protocol Subjects, Efficacy Phase of the US-Canada Study</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<tfoot>
<tr class="First Last"><td align="left" colspan="2">bw, body weight.</td></tr>
<tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Actual mean of the median subcutaneous dose administered in the 12-month efficacy phase.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>One-sided upper 99% confidence interval: 0.14%.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> was reported in two subjects.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Number of per-protocol subjects <br> (efficacy phase) </td>
<td class="Rrule" align="center" valign="bottom">51</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Weekly dose of Vivaglobin</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mean</td>
<td class="Rrule" align="center">158 mg/kg bw</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Range</td>
<td class="Rrule" align="center">34-352 mg/kg bw</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Mean % previous IGIV dose (range)</td>
<td class="Rrule" align="center">136%<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> (99%-188%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Annual rate of serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span></td>
<td class="Rrule" align="center">0.04 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>/subject year<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Annual rate of any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Rrule" align="center">4.4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>/subject year</td>
</tr>
</tbody>
</table>
<p>Table 9 provides a summary of missed school or work and hospitalization due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, which were also evaluated in the efficacy phase of the study.</p>
<a name="table9"></a><table width="70%">
<caption><span>Table 9: Additional Efficacy Results – Per-protocol Subjects, US-Canada Study</span></caption>
<col align="left" valign="middle" width="65%">
<col align="center" valign="middle" width="35%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Number of per-protocol subjects (efficacy phase)</td>
<td class="Rrule" align="center">51</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total number of subject days </td>
<td class="Rrule" align="center">18,949</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total number of days missed school/work due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (%)</td>
<td class="Rrule" align="center">192 (1.0%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Annual rate missed school/work due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (days/subject year)</td>
<td class="Rrule" align="center">3.70</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total number of days hospitalized due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (%)</td>
<td class="Rrule" align="center">12 (&lt;0.1%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Annual rate of hospitalization (days/subject year)</td>
<td class="Rrule" align="center">0.23</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-11.2"></a><p></p>
<h2>14.2	Europe-Brazil Study</h2>
<p class="First">In a clinical study of Vivaglobin conducted in Europe and Brazil, 60 adult and pediatric subjects with PI were switched to weekly subcutaneous administration of Vivaglobin for 6 months. Forty-nine (49) subjects had been on IGIV, and 11 subjects had been treated long-term with another IGSC before entering the study. The 47 per-protocol subjects received a weekly mean dose of 89 mg/kg body weight of Vivaglobin (range: 51 to 147 mg/kg), which was 101% (range: 81% to 146%) of their previous immune globulin treatment.</p>
<p>The annualized rate of serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> was 0.04 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per subject year (one-sided upper 99% confidence interval: 0.21). The annualized rate of any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was 4.3 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per subject year).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-12"></a><p></p>
<h1>15	REFERENCES</h1>
<ol>
<li>Cayco AV, Perazella MA, Hayslett JP. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. <span class="Italics">J Am Soc Nephrol </span>1997;8:1788-1793.</li>
<li>Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. <span class="Italics">Neurology</span> 1994;44:223-226.</li>
<li>Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span> with intravenous immunoglobulin in elderly patients. <span class="Italics">Lancet</span> 1986;2:217-218.</li>
<li>Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. <span class="Italics">Am J Hematol</span> 2000;65:30-34.</li>
<li>Gabor EP. <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> after intravenous immune globulin therapy. <span class="Italics">Ann Intern Med</span> 1997;127:1130.</li>
<li>Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> following intravenous immune globulin therapy. <span class="Italics">Transfusion</span> 1986;26:410-412.</li>
<li>Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> after high-dose intravenous Ig. <span class="Italics">Blood</span> 1993;15:3789.</li>
<li>Wilson JR, Bhoopalam N, Fisher M. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> associated with intravenous immunoglobulin. <span class="Italics">Muscle Nerve</span> 1997;20:1142-1145.</li>
<li>Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. <span class="Italics">In vivo</span> administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. <span class="Italics">J Autoimmun</span> 1999;13:129-135.</li>
<li>Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> after the infusion of IVIG. <span class="Italics">Transfusion</span> 2001;41:264-268.</li>
<li>Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin<span class="Italics">. Trans Med Rev</span> 2003;17:241-251.</li>
<li>Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. <span class="Italics">Lancet</span> 1972;1:1208-1212.</li>
<li>Waniewski I, Gardulf A, Hammarström L. Bioavailability of γ-globulin after subcutaneous infusions in patients with common variable <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>. <span class="Italics">J Clin Immunol</span> 1994;14:90-97.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-13.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">Vivaglobin is supplied in a single-use, tamper-evident vial containing 160 mg protein per mL of preservative-free liquid. Each vial label contains a peel-off strip with the vial size and product lot number for use in recording doses in a patient treatment record. The components used in the packaging for Vivaglobin are latex-free.</p>
<p>The following dosage forms are available:</p>
<table width="80%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="32%">
<col align="left" valign="middle" width="18%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th align="left">NDC Number</th>
<th align="center">Vial Size</th>
<th align="left">Packaging</th>
<th align="center">Grams Protein</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">0053-7596-01</td>
<td align="center"> 3 mL</td>
<td align="left">Single vial</td>
<td align="center">0.48 g</td>
</tr>
<tr>
<td align="left">0053-7596-10</td>
<td align="center">10 mL</td>
<td align="left">Single vial</td>
<td align="center">1.6 g</td>
</tr>
<tr class="Last">
<td align="left">0053-7596-20</td>
<td align="center">20 mL</td>
<td align="left">Single vial</td>
<td align="center">3.2 g</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-13.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<p class="First">Store in the refrigerator at 2–8°C (36–46°F). Vivaglobin is stable for the period indicated by the expiration date on its label. Do not freeze. Do not use product that has been frozen. Do not shake. Keep Vivaglobin in its original carton to protect it from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-14.1"></a><p></p>
<h2>17.1	Self-Administration</h2>
<p class="First">If self-administration is appropriate, ensure that the patient receives instructions and training on subcutaneous administration in the home setting. This should include the type of equipment to be used and information on its maintenance, demonstration of proper infusion techniques, selection of appropriate infusion sites (e.g., abdomen, thigh, upper arm, and/or lateral hip), maintenance of a treatment diary/log book, and measures to be taken in case of adverse reactions.</p>
<p>Make sure your patients understand how important it is that they adhere to the weekly administration schedule for Vivaglobin in order to maintain the steady levels of IgG in their blood. It is recommended that patients keep their treatment diary/log book current by recording, after each infusion, the time, date, dose, and any reactions, and by removing the peel-off portion of the label (containing the lot number) from the product vial and placing it in the treatment diary/log book.</p>
<p>Tell your patients that mild to moderate local injection-site reactions (e.g., <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>) are a common side effect of subcutaneous therapy, but to contact their healthcare professional if a local reaction lasts longer than 4 days or is severe. With subcutaneous infusions, it is important that the needle is long enough to reach the subcutaneous tissue and that the actual point of injection be changed with each infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-14.2"></a><p></p>
<h2>17.2	Additional Information for Patients</h2>
<ul>
<li>
<span class="Bold">Dose adjustments</span> – Tell patients that they may be tested regularly to make sure they have the correct levels of Vivaglobin (IgG) in their blood. These tests may result in adjustments to their dose.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span> – Inform patients of the early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to Vivaglobin (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>). Advise them of appropriate actions to take in the event of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</li>
<li>
<span class="Bold">Interference with vaccines</span> – Inform patients that administration of immunoglobulin may interfere with the response to live virus vaccines (e.g., <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>) and to notify their immunizing physician of recent therapy with Vivaglobin.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome (AMS)</span> – Inform patients of the symptoms of AMS, including severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, sensitivity to light, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</li>
<li>
<span class="Bold">Reactions reported with IGIV treatment</span> – Advise patients to be aware of and immediately report the following signs and symptoms to their healthcare professional:<ul class="Disc">
<li>Decreased urine output, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, which may suggest kidney problems.</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, changes in mental status, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and other manifestations of thrombotic and embolic events.</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, increased heart rate, yellowing of the skin or eyes, and dark-colored urine, which may suggest <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.</li>
<li>Severe breathing problems, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, drops in blood pressure, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, which may suggest <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> (a condition typically occurring within one to six hours following transfusion).</li>
</ul>
</li>
<li>
<span class="Bold">Transmissible infectious agents</span> – Inform patients that Vivaglobin is made from human plasma (part of the blood) and may contain infectious agents that can cause disease.</li>
</ul>
<p class="First">The attached Vivaglobin "Information for Patients" contains more detailed instructions for patients who will be self-administering Vivaglobin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FDA"></a><a name="section-14.3"></a><p></p>
<h2>FDA-Approved Patient Labeling</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Vivaglobin (Pronounced VEE-vah-glow-bin)<br>Immune Globulin Subcutaneous (Human)</span></p>
<p><span class="Bold">Information for patients</span></p>
<p>This leaflet contains important information about Vivaglobin. <span class="Italics">Please read it carefully before using this medicine. </span>This information does not take the place of talking with your healthcare professional, and it does not include all of the available information about Vivaglobin. If you have any questions after reading this, ask your healthcare professional.</p>
<p><span class="Bold">What is the most important information I should know about Vivaglobin?</span></p>
<ul class="Disc"><li>Vivaglobin is supposed to be infused under your skin only. DO NOT inject Vivaglobin into a blood vessel (vein or artery).</li></ul>
<p><span class="Bold">What is Vivaglobin?</span></p>
<p>Vivaglobin is a solution that contains proteins, called immunoglobulins, from plasma (the liquid part of human blood). These proteins are used to treat primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (also called PI). People with primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> get a lot of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> because their immune system doesn't function properly.</p>
<p>Vivaglobin contains the antibody <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG), which helps your body fight off <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria and viruses. Vivaglobin contains no preservatives, and the packaging contains no latex.</p>
<p><span class="Bold">Who should <span class="Underline">NOT</span> take Vivaglobin?</span></p>
<p>Do not take Vivaglobin if you have had a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> or a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to other immunoglobulin medicines. </p>
<p>Tell your doctor if you have a condition called selective (or severe) immunoglobulin A (IgA) deficiency. This may mean you have a much greater chance of having an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Vivaglobin.</p>
<p>Tell your doctor if you have a history of heart or blood vessel disease or blood clots, have thick blood, or have been immobile for some time. These things may increase your risk of having a blood clot after using Vivaglobin. </p>
<p><span class="Bold">How should I take Vivaglobin?</span></p>
<p>You will use a needle to infuse Vivaglobin under your skin. Do not use Vivaglobin until you have been taught how to infuse it. For the treatment to work properly, you must follow the dose and treatment schedule that your doctor gives you. Your doctor will obtain blood samples regularly to make sure you are getting the right amount of Vivaglobin.</p>
<p>Carefully read the "Instructions for Use" located at the end of this leaflet before you start your infusion. If you have any questions about the "Instructions for Use," discuss them with your doctor before you start to use Vivaglobin.</p>
<p><span class="Bold">What should I avoid while taking Vivaglobin?</span></p>
<p>Vivaglobin can make some vaccines (like <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>/<span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>/<span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> or <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> vaccines) not work as well for you. Before you get any vaccines, tell your doctor or healthcare professional that you take Vivaglobin. </p>
<p>Do not mix other products with the Vivaglobin solution.</p>
<p>Tell your doctor if you are pregnant or plan to become pregnant, or if you are nursing.</p>
<p><span class="Bold">What are possible side effects of Vivaglobin?</span></p>
<p>The most common side effects with Vivaglobin occur in the area of the skin where the infusion needle is placed. These include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Most of these side effects go away within 1 to 2 days. Tell your doctor if any of these side effects last for 4 days or more. These side effects may happen less and less with continued regular use of Vivaglobin.</p>
<p>Other side effects that might occur include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">Upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></li>
<li>Fast heart rate</li>
<li><span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">Chest tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle ache</span></li>
</ul>
<p>Tell your doctor right away or go to the emergency room if you have <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. These could be signs of a bad <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Tell your doctor right away if you get any of the following symptoms. They could be signs of a serious problem.</p>
<ul class="Disc">
<li>Reduced urination, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your legs. These could be signs of a kidney problem.</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, warmth, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or a lump in your legs or arms. These could be signs of a blood clot.</li>
<li>Bad <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and sensitivity to light. These could be signs of a brain <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> called <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</li>
<li>Brown or red urine, fast heart rate, <span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> or eyes. These could be signs of a blood problem.</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> or trouble breathing.</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> over 100°F. This could be a sign of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p>Tell your doctor about any side effects that concern you. You can ask your doctor to give you more information that is available to healthcare professionals.</p>
<p><span class="Bold">How do I use Vivaglobin?</span></p>
<p>Vivaglobin is infused under the skin (subcutaneously). With proper training, you can infuse it on your own. Do not inject Vivaglobin into a blood vessel (vein or artery).</p>
<p>Your doctor will determine the appropriate dose and schedule for your treatment.</p>
<p>Your healthcare professional will teach you how to infuse Vivaglobin. Always follow the instructions you receive. The instructions below are general guidelines for using Vivaglobin. Use them only as an aid once you have learned the proper way to infuse Vivaglobin. Call your healthcare professional if you are not sure about the procedure or if you have any questions about these instructions.</p>
<p><span class="Bold">Instructions for use</span></p>
<p><span class="Italics">Do not use Vivaglobin until you have been taught how to use it by your doctor. For the treatment to work, you must carefully follow your doctor's instructions. The instructions below are provided to you as a guide. If you have any questions about these instructions, it is important that you discuss them with your doctor before you start to use Vivaglobin.</span></p>
<p>Keep Vivaglobin and all other medicines away from children.</p>
<p>Vivaglobin comes in single-use vials. Keep these vials in their storage box in the refrigerator at 2-8°C (36-46°F) until you are ready to use them. Do not freeze. Vivaglobin has no preservatives added, so it is important to throw away any Vivaglobin leftover in a vial after it is opened.</p>
<table width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2"><dl class="Disc">
<dt>1.</dt>
<dd>Take the Vivaglobin vial(s) out of the refrigerator and let it warm up to room temperature. Clean a table or other flat surface. Get together all of the supplies you need for your infusion. Generally, you will need: 					<ul class="Disc">
<li>Vivaglobin vial(s)</li>
<li>Treatment diary or logbook</li>
<li>Infusion pump</li>
<li>Infusion administration tubing</li>
<li>Needle or catheter sets (for subcutaneous infusion)</li>
<li>Y-site connectors (if needed)</li>
<li>Alcohol wipes</li>
<li>Antiseptic skin preps</li>
<li>Syringes</li>
<li>Transfer needles</li>
<li>Gauze and tape, or transparent dressing</li>
<li>Transparent dressing</li>
<li>Sharps container</li>
<li>Gloves (if recommended by your healthcare professional)</li>
</ul>
</dd>
</dl></td></tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>2.</dt>
<dd>Thoroughly wash and dry your hands (Figure 1). If you have been told to wear gloves when preparing your infusion, put the gloves on.</dd>
</dl></td>
<td align="right"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-05.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>3.</dt>
<dd>Carefully look at the liquid in each vial of Vivaglobin (Figure 2). It should look clear and be colorless to light brown. Check for particles or color changes. Do not use the vial if: 					<ul class="Disc">
<li>The liquid looks cloudy, contains particles, or has changed color.</li>
<li>The protective cap is missing.</li>
<li>The expiration on the label has passed.</li>
</ul>
</dd>
</dl></td>
<td align="right"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-06.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>4.</dt>
<dd>Take the protective cap off of each vial (Figure 3).</dd>
</dl></td>
<td align="right"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-07.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>5.</dt>
<dd>Clean each vial stopper with an alcohol wipe (Figure 4). Let the stopper dry.</dd>
</dl></td>
<td align="right"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-08.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>6.</dt>
<dd>Using aseptic technique as instructed by your healthcare professional, attach a transfer needle to the syringe tip (Figure 5).</dd>
</dl></td>
<td align="right"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-09.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>7.</dt>
<dd>Transfer the Vivaglobin from the vial to the syringe as follows: 					<ul class="Disc">
<li>Pull out the plunger on the syringe to fill it with air. The amount of air should be the same as the amount of Vivaglobin you will transfer from the vial.</li>
<li>Put the Vivaglobin vial on a flat surface. Keeping the vial upright, insert the transfer needle into the center of the rubber stopper.</li>
<li>Check that the tip of the needle is not in the liquid. Then, push the plunger on the syringe down. This will inject the air from the syringe into the airspace of the vial.</li>
<li>Leaving the needle and syringe in the stopper, carefully turn the vial upside down (Figure 6).</li>
<li>Slowly pull back on the plunger to fill the syringe with Vivaglobin.</li>
<li>Take the filled syringe and needle out of the stopper. Take off the needle and throw it away in the sharps container.</li>
</ul>
<p class="First">If you are using more than one vial, your healthcare professional will show you how to fill the syringe before starting the infusion.</p>
</dd>
</dl></td>
<td align="right" valign="middle"><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-10.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>8.</dt>
<dd>Prepare the infusion pump (following the manufacturer's instructions) and prime the administration tubing (Figure 7). To prime the tubing, connect the syringe filled with Vivaglobin to the administration tubing and gently push on the syringe plunger to fill the tubing with Vivaglobin.</dd>
</dl></td>
<td align="right"><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-11.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>9.</dt>
<dd>Select an area on your abdomen, thigh, upper arm, or on the side of upper leg/hip for the infusion (Figure 8). Do not insert the needle in the same place it was the last time you infused Vivaglobin. 					<ul class="Disc">
<li>Your healthcare professional will help you decide which part of your body is best for infusion.</li>
<li>Your healthcare professional will tell you how many injection sites you need to use and how much Vivaglobin to infuse at each site. Generally, doses more than 15 mL should be divided and infused at a different site.</li>
<li>Do not use more than 3 injection sites at the same time if you are a child weighing less than 99 pounds, more than 6 sites at the same time of you are under age 65, or more than 4 sites at the same time if you are over age 65. If needed, you can use more injection sites consecutively.</li>
<li>If you are using more than one injection site, be sure that each site is at least 2 inches apart.</li>
</ul>
<p class="First">Clean the skin at each site with an antiseptic skin prep (Figure 9). Let the <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">skin dry</span>. </p>
</dd>
</dl></td>
<td align="right">
<img alt="Figure 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-12.jpg"><br><img alt="Figure 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-13.jpg">
</td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>10.</dt>
<dd>Depending on your body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, use your thumb and forefinger to either pinch together the skin around the injection site or spread and flatten the skin around the injection site. Insert the needle under the skin (Figure 10).</dd>
</dl></td>
<td align="right"><img alt="Figure 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-14.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>11.</dt>
<dd>After you have inserted the infusion needle, put sterile gauze and tape or a transparent dressing over the injection site (Figure 11). This will keep the needle from coming out.</dd>
</dl></td>
<td align="right"><img alt="Figure 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-15.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>12.</dt>
<dd>Do not inject Vivaglobin into a blood vessel. To test for this, attach a sterile syringe to the end of the administration tubing. Pull the plunger back gently (Figure 12). If you see any blood in the tubing, take the needle out of the injection site. Throw away the administration tubing and needle and start over at a different site with new administration tubing and a new needle.</dd>
</dl></td>
<td align="right"><img alt="Figure 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-16.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>13.</dt>
<dd>Follow the instructions on the infusion pump (Figure 13) to connect the administration tubing and set the infusion rate. (Your doctor will tell you what rate to use for your Vivaglobin infusion. Generally, you will not infuse faster than 20 mL per hour per site.)  Turn on the pump.</dd>
</dl></td>
<td align="right"><img alt="Figure 13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-17.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>14.</dt>
<dd>Peel off the removable part of the label from the Vivaglobin vial(s). Put this label in your treatment diary or logbook with the date and time of the infusion and the exact amount of Vivaglobin that you infused (Figure 14).</dd>
</dl></td>
<td align="right"><img alt="Figure 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-18.jpg"></td>
</tr>
<tr class="Toprule">
<td align="left"><dl class="Disc">
<dt>15.</dt>
<dd>When all the Vivaglobin has been infused, turn off the pump. Take off the dressing and take the needle out of the injection site. Throw away the used supplies in the sharps container as directed by your healthcare professional (Figure 15).</dd>
</dl></td>
<td align="right"><img alt="Figure 15" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-19.jpg"></td>
</tr>
<tr class="Last Toprule"><td align="left" colspan="2"><dl class="Disc">
<dt>16.</dt>
<dd>Clean and store the infusion pump, following the manufacturer's care instructions.</dd>
</dl></td></tr>
</tbody>
</table>
<p>Be sure to tell your doctor about any problems you have doing your infusions. Your doctor may ask to see your treatment diary or logbook, so be sure to take it with you each time you visit the doctor's office.</p>
<p>Call your doctor for medical advice about side effects. You can also report side effects to the FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></p>
<p>Manufactured by:<br><span class="Bold">CSL Behring GmbH</span><br>35041 Marburg, Germany<br>US License No. 1765</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 3 mL Label</span></p>
<p><span class="Bold">3 mL<br>NDC 0053-7596-01</span></p>
<p><span class="Bold">Immune Globulin<br>Subcutaneous (Human)</span></p>
<p><span class="Italics"><span class="Bold">Viva</span>globin</span><span class="Sup">®</span></p>
<p>Store at 2–8°C (36–46°F).<br>Do not freeze. Store vial in box.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 3 mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-20.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 3 mL Carton</span></p>
<p><span class="Bold">NDC 0053-7596-01<br>3 mL</span></p>
<p><span class="Bold">Immune Globulin<br>Subcutaneous (Human)</span></p>
<p><span class="Italics"><span class="Bold">Viva</span>globin</span><span class="Sup">®</span></p>
<p>One Single Use Vial</p>
<p><span class="Bold">Rx only</span></p>
<p>EXP.:</p>
<p>LOT:</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 3 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88eac3b8-55a5-4451-9d25-c30e43ab7068&amp;name=vivaglobin-21.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIVAGLOBIN 		
					</strong><br><span class="contentTableReg">human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin g</span> solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7596</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">Immunoglobulin G</span></strong> (Human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">Immunoglobulin G</span>) </td>
<td class="formItem">Human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">Immunoglobulin G</span></td>
<td class="formItem">160 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7596-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0053-7596-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0053-7596-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125115</td>
<td class="formItem">01/09/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring LLC
							(931896963)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring GmbH</td>
<td class="formItem"></td>
<td class="formItem">326530474</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>be002d84-ee9f-4a1e-a396-3a59a4e5b834</div>
<div>Set id: 88eac3b8-55a5-4451-9d25-c30e43ab7068</div>
<div>Version: 8</div>
<div>Effective Time: 20100715</div>
</div>
</div> <div class="DistributorName">CSL Behring LLC</div></p>
</body></html>
